45P Rare and non-canonical ALK fusion in advanced NSCLC: Heterogeneous clinical outcomes with ALK inhibitors
Salvatore Intagliata, Nicoletta Bianchi, Graciela Ghirardi, M. Cardisperi et autres
ALK rearrangements define a clinically relevant subset of non-small cell lung cancer (NSCLC) sensitive to ALK tyrosine kinase inhibitors (TKIs). While EML4–ALK is the most frequent fusion, next-generation sequencing (NGS) has enabled the identification of rare ALK fusion partners, whose clinical behavior …
it (code pays fourni par la source)
0 citations
ESMO Open